Novel gene therapy approach to treat lymphedema
Lymphedema is a disabling condition of localised accumulation of fluid in a tissue caused by a compromised lymphatic system. It is an incurable disease that affects millions of people worldwide and is most often a consequence of cancer treatment. The main objective of the EU-funded TheraLymph project is to develop treatment to ameliorate this condition using a non-integrative gene therapy approach. The project consortium's translational research programme brings together scientists and physicians from 5 European countries and will be focused on patients who developed lymphedema after breast cancer. Research will determine risk factors for lymphedema and key molecular players involved in the lymphatic dysfunction. The project goal is to validate the best molecule combination for gene therapy and to finalise phase I/II clinical trials at the affiliated hospital.
Fields of science
Call for proposal
See other projects for this call